- Product Description
- Data & Figures
- Technical Library
- Reference Literature
- Downloads
The PromoCell Cancer Cell Line Medium XF is a cell culture medium developed for the standardized in vitro cultivation of established human cancer cell lines. Its serum-free and xeno-free formulation provides a culture environment devoid of all stimuli originating from non-defined materials. Thus, it has no ill-defined components such as fetal calf serum, extracts or hydrolysates and exhibits very low lot-to-lot variability.
Components:The PromoCell Cancer Cell Line Medium XF consists of a bottle of Basal Medium and one vial of SupplementMix. Adding the SupplementMix to the Basal Medium results in the complete medium
Note: Culture vessels need to be coated. For coating we recommend using Human Fibronectin Solution (C-43060) or Vitronectin (C-69201).
Key features:
- Suitable for long-term routine culture of adherently growing established human cancer cell lines
- Compatible with most commonly used human cancer cell lines
- Xeno-free and serum-free formulation
List of cell types tested for serial passage with the PromoCell Cancer Cell Line Medium XF:
Tissue | Tested Cell Lines | Cell Lines Origin | Remarks |
---|---|---|---|
Brain | BV2 | immortalized murine primary microglial cells | Coat with Fibronectin:1 µg/cm2 |
Breast | MCF-7 | pleural effusion of metastatic human breast adenocarcinoma | Coat with Fibronectin:1 µg/cm2 |
Colon | HT-29 | human colon adenocarcinoma | Coat with Vitronectin:0.5 µg/cm2 |
Connective tissue | HT1080 | human fibrosarcoma | Coat with Fibronectin:1 µg/cm2 |
Liver | HepG2 | hepatocellular carcinoma of the human liver | Coat with Vitronectin:0.5 µg/cm2 |
Lung | A-549 | human lung carcinoma | Coat with Vitronectin:0.5 µg/cm2 |
Prostate | LNCaP | lymph node metastasis of human prostate adenocarcinoma | 3D culture in C-28070 is recommended |
Peripheral blood | MV-4-11 | Human acute myelogenous leukemia (suspension) | No coating required |
Bone marrow | KG-1 | Human acute myelogenous leukemia (suspension) | No coating required |
Kidney | ACHN | Human Renal Cell Carcinoma | Coat with Fibronectin:1 µg/cm2 |
Brain | A172 | Human Glioblastoma | Coat with Fibronectin:1 µg/cm2 |
Skeletal muscle | C2C12 | Mouse Myoblasts | Coat with Fibronectin:1 µg/cm2 |
Skin | B16-F10 | Mouse Melanoma | Coat with Fibronectin:1 µg/cm2 |
Abelson murine leukemia virus-induced tumor | RAW264.7 | Mouse Macrophage | Coat with Fibronectin:1 µg/cm2 |
Brain, neuroectodermal | Neuro-2a | Mouse Neuroblastoma | Coat with Fibronectin:1 µg/cm2 |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他站友认领”
MaggotsFasterThanScalpelinWoundDebridement
December19,2011—Maggotdebridementtherapy(MDT)appearstobemoreeffectiveforwounddebridementcomparedwithconventionaltherapy,butonlyat1week;afterthattime,anothertypeofdressingshouldbeused,newresearchsuggests.
KristinaOpletalovà,MD,fromtheDepartmentofDermatology,UniversityofCaen,France,andcolleaguespublishedonlineDecember19intheArchivesofDermatology.
MedicalmaggotswereapprovedbytheUSFoodandDrugAdmiNISTrationasamedicaldeviceforwounddebridementin2004.Accordingtotheresearchers,useofmaggotsintreatingwoundsisassociatedwitheffectivewounddebridement,antibacterialeffects,andstimulationofwoundhealing.
However,theypointout,"[r]elativelyfewclinicalstudieshavebeenconductedandtheresultsarenotclear,partlyowingtomethodologicassessmentproblems."
InthecurrentProspective,randomizedcontrolled,phase3clinicaltrial,theresearcherssoughttodeterminetheefficacyofbaggedlarvaeonwounddebridementincomparisonwithconventionaltreatment.
TheprimaryobjectivewastocomparethemeanpercentageofsloughinwoundstreatedwithMDTwiththatofconventionaltreatmentatday15.Thestudyincluded119patientswithanonhealing,sloughywoundthatwas40cm2orsmallerandlessthan2cmdeep.Patientsalsohadananklebrachialindexof0.8orhigher.
Treatmentwasadministeredduringa2-weekhospitalstay.Conventionaltreatmentconsistedofsurgicaldebridement3timesaweekwithascalpel,withuseoftopicalanesthesia.TheMDTwasadministeredusinganencloseddressing(Vitapad,BioMondeLaboratories)containing80sterilemaggots.Atdischarge,aconventionaldressingwasapplied,andpatientswerefollowed-upatday30.
DebridementbyMDTwassignificantlyfasterthansurgicaldebridementduringthefirstweekoftreatment,reachingthesamelevelthecontrolgroupreachedatday15.NobenefitforMDTcomparedwithconventionaltreatmentinhealingrateswasobserved.Atday8,54.5%intheMDTgroupvs66.5%inthecontrolgroup(P=.04)hadevidenceofsloughandwoundhealing.However,byday15,themeanpercentageofsloughwas55.4%intheMDTgroupand53.8%inthecontrolgroup(P=.78).
"AthoughMDTshowsnosignificantbenefitatday15comparedwithconventionaltreatment,debridementbyMDTissignificantlyfasterandoccursduringthefirstweekoftreatment,"theresearchersconclude."Becausethereisnobenefitincontinuingthetreatmentafter1week,anothertypeofdressingshouldbeusedafter2or3applicationsofMDT."
Painscoresweresimilarandmildinbothgroups,althoughincontrasttoconventionaltreatment,MDTwasperformedwithouttopicalanesthesia.
Accordingtotheresearchers,noneofthepatientswerereticentaboutundergoingMDT."[A]crawlingsensationonthewoundwasrarelyandalmostequallynotedinbothgroups,revealingthatthesensationwassubjective,"Dr.Opletalovàandcolleaguespointout.
TwoquestionsregardingMDTremainunanswered,theauthorsnote."Candebridementbeimprovedusingmoremaggotsperdressing?Ifso,wouldthesedressingsbemorepainful?Furtherstudiesareneededtoanswerthesequestions."
ThestudywassupportedbygrantsfromtheClinicalResearchHospitalProgramandfromtheFrenchSocietyofDermatology.Theauthorshavedisclosednorelevantfinancialrelationships.
1. 姜黄素是一个典型的HAT抑制剂。
2. 针对P300: 在大约10年前,Cole和他的同事设计出了一种p300/CBP抑制剂,发表在nature杂志上。
希望能帮到你,望采纳!
天然产物,大多都有颜色,
存在干扰,多数情况下需要做样品的阴性对照,
尽量能用荧光的方法,
之前我们做过,将两个试剂盒的方法合并后,做的,
效果还可以
支原体培养则是取样后在培养基上培养,看有多少支原体菌落会长出,是比较直观和可信的结果。
总体来讲,这两种检查手段可信度都较高,结合一起,不仅可以可靠的知道有无解脲支原体感染,还能知道感染是否严重。
暂无品牌问答